StreetInsider.com News Articles

Form 6-K NuCana plc For: Jan 06

Tue, 06 Jan 2026 08:12:00 -0500

si-local-file:///var/storage/secattach/20260106/25809842.html

NuCana names Theresa Bruce as chief operating officer

Tue, 06 Jan 2026 08:00:18 -0500

NuCana plc (NASDAQ: NCNA) appointed Theresa Bruce as chief operating officer, effective January 1, 2026, according to a company statement.

Bruce brings more than 25 years of experience in oncology research and development. She previously served as senior vice president of clinical operations at NuCana and held senior leadership roles at clinical research organizations and biotechnology companies, including senior vice president positions at Chiltern and Veristat. She also served as chief operating officer at Nexus Oncology.

"Theresa brings more than two decades of experience leading global clinical development programs across biotechnology companies and clinical research organizations," said Hugh S. Griffith, NuCana's founder

NuCana Appoints Theresa Bruce as Chief Operating Officer

Tue, 06 Jan 2026 08:00:00 -0500

EDINBURGH, United Kingdom, Jan. 06, 2026 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”), a clinical-stage biopharmaceutical company focused on improving treatment outcomes for patients with cancer, announced the appointment of Theresa Bruce as Chief Operating Officer, effective January 1, 2026.

“We are delighted to appoint Theresa as Chief Operating Officer and welcome her to NuCana’s executive leadership team,” said Hugh S. Griffith, NuCana’s Founder and Chief Executive Officer. “Theresa brings more than two decades of experience leading global clinical development programs across biotechnology companies and clinical research organizations. Her operational leadership

NuCana Appoints Theresa Bruce as Chief Operating Officer

Tue, 06 Jan 2026 08:00:00 -0500

Form 6-K NuCana plc For: Dec 17

Wed, 17 Dec 2025 08:12:00 -0500

si-local-file:///var/storage/secattach/20251217/25750254.html

Form 6-K NuCana plc For: Dec 10

Wed, 10 Dec 2025 08:16:00 -0500

si-local-file:///var/storage/secattach/20251210/25721460.html

NuCana shows clinical activity for NUC-7738 in melanoma patients

Wed, 10 Dec 2025 08:03:36 -0500

NuCana plc (NASDAQ: NCNA) presented clinical data for its drug candidate NUC-7738 at the European Society for Medical Oncology Immuno-Oncology Congress in London. The data showed clinical activity in patients with PD-1 inhibitor-resistant metastatic melanoma when NUC-7738 was combined with pembrolizumab.

The treatment produced two partial responses, including one confirmed response, and seven cases of stable disease among patients who had progressive disease before starting treatment. One case of stable disease converted to a complete metabolic response with no detectable active disease.

Nine patients have been treated in the Expansion Cohort, part of a planned enrollment of up to 28 additional patients.

NuCana shows clinical activity for NUC-7738 in melanoma patients

Wed, 10 Dec 2025 08:03:36 -0500

Nine patients have been treated in the Expansion Cohort, part of a planned enrollment of up to 28 additional patients.

NuCana Presents Latest Data Demonstrating Clinical Activity and Favorable Safety for NUC-7738 in Patients with PD-1-Resistant Melanoma

Wed, 10 Dec 2025 08:00:00 -0500

Data Presented at ESMO IO 2025 include Partial Responses, Durable Disease Control, and No New Safety Signals, Reinforcing Earlier Findings

EDINBURGH, United Kingdom, Dec. 10, 2025 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”) presented the latest clinical data at the annual European Society for Medical Oncology (“ESMO”) Immuno-Oncology Congress, December 10-12, 2025, in London.

The data from patients with PD-1 inhibitor-resistant metastatic melanoma treated with NUC-7738 in combination with pembrolizumab continue to demonstrate clinical activity and a favorable safety profile. All patients had progressive disease prior to starting treatment. Clinical activity

NuCana Presents Latest Data Demonstrating Clinical Activity and Favorable Safety for NUC-7738 in Patients with PD-1-Resistant Melanoma

Wed, 10 Dec 2025 08:00:00 -0500

Data Presented at ESMO IO 2025 include Partial Responses, Durable Disease Control, and No New Safety Signals, Reinforcing Earlier Findings

Form 6-K NuCana plc For: Nov 13

Thu, 13 Nov 2025 16:18:00 -0500

si-local-file:///var/storage/secattach/20251113/25607648.html

NuCana Reports Third Quarter 2025 Financial Results and Provides Business Update

Thu, 13 Nov 2025 16:01:00 -0500

Announced Encouraging Data on both NUC-7738 and NUC-3373

Initial Data from the Expansion Study of NUC-7738 Expected in Q4 2025 with Final Data Expected in 2026

Compliant with All Nasdaq Continued Listing Criteria

Well Capitalized with Anticipated Cash Runway into 2029

EDINBURGH, United Kingdom, Nov. 13, 2025 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”) announced financial results for the third quarter ended September 30, 2025 and provided an update on its clinical development program with its two lead anti-cancer medicines.

“We recently

NuCana Reports Third Quarter 2025 Financial Results and Provides Business Update

Thu, 13 Nov 2025 16:01:00 -0500

Announced Encouraging Data on both NUC-7738 and NUC-3373

Initial Data from the Expansion Study of NUC-7738 Expected in Q4 2025 with Final Data Expected in 2026

Compliant with All Nasdaq Continued Listing Criteria

Well Capitalized with Anticipated Cash Runway into 2029

“We recently

Form 6-K NuCana plc For: Nov 05

Wed, 05 Nov 2025 08:12:00 -0500

si-local-file:///var/storage/secattach/20251105/25558237.html

NuCana secures patent for cancer drug NUC-7738 in China

Wed, 05 Nov 2025 08:03:55 -0500

NuCana plc (NASDAQ: NCNA) announced that the China National Intellectual Property Administration has granted a composition-of-matter patent for its cancer drug candidate NUC-7738.

The patent (ZL 202010794701.2) covers the chemical structure of NUC-7738, which is currently being evaluated in a Phase 1/2 clinical study called NuTide:701. The study examines the drug in combination with pembrolizumab for patients with melanoma that is refractory or resistant to PD-1 inhibitor treatment.

NuCana stated that NUC-7738 now has patent protection consisting of more than 85 issued patents worldwide. The Edinburgh-based biopharmaceutical company described the Chinese patent as a key component of its intellectual property strategy for

NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in China

Wed, 05 Nov 2025 08:00:00 -0500

EDINBURGH, United Kingdom, Nov. 05, 2025 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”) announced that the China National Intellectual Property Administration (“CNIPA”) has granted an important patent covering the composition of matter for NUC-7738. This patent (ZL 202010794701.2) is expected to serve as a key component of the patent protection for NUC-7738, which currently consists of over 85 issued patents worldwide. The composition of matter patent covers the chemical structure of NUC-7738, NuCana’s novel anti-cancer agent currently being evaluated in a Phase 1/2 clinical study (NuTide:701) in combination with pembrolizumab for patients with

NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in China

Wed, 05 Nov 2025 08:00:00 -0500

Form 6-K NuCana plc For: Oct 20

Mon, 20 Oct 2025 08:00:00 -0500

si-local-file:///var/storage/secattach/20251020/25474126.html

NuCana Presents Encouraging Data on NUC-7738 in Combination with PD-1 Inhibitors using Primary Patient-Derived Organoids and Autologous Tumor-Infiltrating Lymphocytes at the ESMO Congress 2025

Sat, 18 Oct 2025 08:00:00 -0500

NUC-7738 Synergizes with PD-1 Inhibitors to Promote Cancer Cell Death

Data Reinforces Mechanism of Action along with Efficacy and Safety Profile of NUC-7738

BERLIN, Oct. 18, 2025 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”) presented data at the European Society for Medical Oncology Congress 2025 (“ESMO”) on a new model system investigating the synergistic effects of NUC-7738 and PD-1 inhibition in primary organoids derived from patients with renal cell carcinoma (“RCC”).

Using patient-derived organoids (“PDOs”) from ten patients with RCC and autologous tumor-infiltrating lymphocytes (“TILs”), co-culture experiments

NuCana Presents Encouraging Data on NUC-7738 in Combination with PD-1 Inhibitors using Primary Patient-Derived Organoids and Autologous Tumor-Infiltrating Lymphocytes at the ESMO Congress 2025

Sat, 18 Oct 2025 08:00:00 -0500

NUC-7738 Synergizes with PD-1 Inhibitors to Promote Cancer Cell Death

Data Reinforces Mechanism of Action along with Efficacy and Safety Profile of NUC-7738

Using patient-derived organoids (“PDOs”) from ten patients with RCC and autologous tumor-infiltrating lymphocytes (“TILs”), co-culture experiments

Form 6-K NuCana plc For: Oct 14

Tue, 14 Oct 2025 08:16:00 -0500

si-local-file:///var/storage/secattach/20251014/25450932.html

NuCana reports clinical data for NUC-3373 cancer treatment combination

Tue, 14 Oct 2025 08:06:50 -0500

NuCana plc (NASDAQ: NCNA) published clinical trial results for its cancer treatment NUC-3373 in combination with pembrolizumab, an anti-PD-1 therapy. The data from the NuTide:303 study was published on medRxiv preprint server alongside preclinical findings in PLOS ONE journal.

The Phase 1/2b study treated 12 patients with advanced solid tumors who had exhausted standard treatment options and previously received PD-1 inhibitors. Results showed a patient with urothelial carcinoma of the bladder achieved a 100% reduction in tumor lesion size and remained on treatment for over 15 months. A patient with metastatic melanoma resistant to prior pembrolizumab therapy showed an 81% reduction

NuCana reports clinical data for NUC-3373 cancer treatment combination

Tue, 14 Oct 2025 08:06:50 -0500

NuCana Announces Encouraging Data for NUC-3373 in Combination with Anti-PD-1 Therapy

Tue, 14 Oct 2025 08:00:00 -0500

NUC-3373 Plus Pembrolizumab Continues to Show Favorable Efficacy and Safety Profile in Heavily Pre-treated Patients

Latest Data Cut-Off Shows Patient with Melanoma Remains Progression-Free at 23 Months with a Durable Partial Response

Preclinical Data Corroborate Immunogenic Effects of NUC-3373 Observed in Patients

EDINBURGH, United Kingdom, Oct. 14, 2025 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”) announced the publication of new data on NUC-3373. The update includes results from the NuTide:303 clinical study, published on medRxiv, the preprint server for health sciences, together with complementary

NuCana Announces Encouraging Data for NUC-3373 in Combination with Anti-PD-1 Therapy

Tue, 14 Oct 2025 08:00:00 -0500

NUC-3373 Plus Pembrolizumab Continues to Show Favorable Efficacy and Safety Profile in Heavily Pre-treated Patients

Latest Data Cut-Off Shows Patient with Melanoma Remains Progression-Free at 23 Months with a Durable Partial Response

Preclinical Data Corroborate Immunogenic Effects of NUC-3373 Observed in Patients